Division of Urology, University of Colorado Denver School of Medicine, Aurora, Colorado 80045, USA.
Prostate cancer will be diagnosed in one of six men during their lifetimes, and a small portion of these will progress after primary and salvage therapies. For many years, there were few treatment options for these patients after routine hormonal maneuvers, and standard of care since the early 2000s has consisted primarily of docetaxel, which improved survival over the previous first-line therapy mitoxantrone. In recent years, however, new therapies have begun to emerge to treat this devastating form of prostate cancer. This review examines the mechanisms behind these therapeutics and the key trials seeking to validate their clinical use.
Written by:
Rove KO, Flaig TW.
Are you the author?
Reference: Oncology (Williston Park). 2010 Dec;24(14):1308-13, 1318.
PubMed Abstract
PMID: 21294475
UroToday.com Prostate Cancer Section
